Irvine-based heart valve maker Edwards Lifesciences Corp. on Friday reported mixed third-quarter results and gave guidance for the remainder of the year.

The company also said that the Food and Drug Administration approved the use of its Edwards Sapien less-invasive heart valve for patients with aortic valve stenosis who are eligible for surgery but at high risk for serious surgical complications or death.

Get the latest OC business updates for FREE

Edwards posted a third-quarter profit of $69.2 million, up 34% from a year ago and above Wall Street’s estimate of $66.6 million.

Revenue rose 9% to $447.9 million, below analysts’ expectations of $448.2 million. Edwards said that was “consistent with the sales figure preannounced” on Oct. 8.

The device maker said that it expects profit for the current quarter to come in at $90.4 million to $95.2 million, compared with analysts’ expectations of $95.2 million.

Fourth-quarter sales are seen at $490 million to $520 million, compared with consensus estimates of $504.8 million.

Edwards said it expected its 2012 profit to come in at $302.2 million to $307 million, compared to analysts’ estimate of $305.8 million.

The company said it now expects its full-year sales at the bottom of its previous $1.9 billion to $1.97 billion range, above Wall Street’ expectation of $1.89 billion.

Edwards' shares were flat in after-hours trading on Friday after closing down 1% with a market value of about $10 billion.